<DOC>
	<DOCNO>NCT01990352</DOCNO>
	<brief_summary>Primary Objective : To evaluate low BRCA1 protein expression preferential effect response metastatic breast cancer patient treat DNA damage chemotherapy agent , compare historical control Secondary Objective : To evaluate low BRCA1 protein expression preferential effect tumor progression metastatic breast cancer patient treat DNA damage chemotherapy agent , compare historical control</brief_summary>
	<brief_title>Correlate BRCA1 Protein Expression With Response DNA Damaging Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Metastatic breast cancer formalinfixed , paraffin embed primary tumor available test BRCA1 protein expression Adults 18 year age Have resolution acute toxic effect prior chemotherapy radiotherapy NCI CTC grade â‰¤ 1 prior study registration . Be inform investigational nature study provide write informed consent accordance institutional federal guideline prior study specific screening procedure Be willing able comply treatment plan , schedule clinic visit , laboratory oncological test study procedure Have ECOG performance status 0 2 Measurable disease CT RECIST 1.1 evaluate response Adequate bone marrow function define platelet 100 X 109 cells/L , neutrophils 1.5 x 109 cells/L , white blood cell ( WBC ) 3.0 x 109 cells/L hemoglobin 90 gm/L Creatinine &lt; 1.5 mg/dl creatinine clearance &gt; 40 ml/min Liver function test ( AST ALT ) 2 x upper limit normal ( ULN , define per laboratory blood test do ) , total bilirubin 1.5 x ULN ( except patient liver metastasis , ALT and/or ALT 5 time upper limit normal accept ) Myocardial infarction within 6 month registration Brain metastases unless document control post completion local therapy ( surgery and/or radiation therapy ) least four week prior registration Pregnant breast feed woman . Women child bear potential must use effective measure prevent pregnancy receiving pegylated liposomal doxorubicin Have concurrent active nonbreast malignancy except nonmelanoma skin cancer Her2 positive tumor define FDA guideline ( 3+ immunohistochemical staining , define uniform , intense membrane stain 10 % invasive tumor cell , case 2+ stain show gene amplification FISH , express ratio 2 compare HER2 gene chromosome 17 fluorescent signal )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>